Text Size

Chromogranin-A-Derived Peptides and Periodontitis in Diabetic Patients

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2009 by University Hospital, Strasbourg, France.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
University Hospital, Strasbourg, France
ClinicalTrials.gov Identifier:
NCT00399620
First received: November 14, 2006
Last updated: January 9, 2009
Last verified: January 2009
History of Changes
  Purpose

Periodontitis is a chronic disease of the supporting tissue of the teeth, characterized by bleeding and inflamed gingival, resorption of alveolar bone. This disease has a significant impact of the quality of life as the teeth become progressively mobile and may fall out spontaneously if no treatment is provided. Periodontal disease has been cited as the sixth complication of diabetes mellitus.Chromogranins / secretogranins are a family of proteins present in nervous endocrine and immune cells, released with catecholamines during stress situations. Chromogranin A (CGA) is the major member of this family.The aim of this study is to determine the level of CGA and its derived peptides in the gingival crevicular fluid (GCF) of health or diabetic patients with and without periodontitis.Then, we want to determine the antimicrobial activity of these peptides.


Condition Intervention
Periodontitis and Diabetitis
 Procedure: Gingival crevicular fluid samples (this procedure is added to the subject usual medical follow-up).

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Chromogranin-A-Derived Peptides in the Gingival Crevicular Fluid and the Saliva of Diabetic Patients With or Without Periodontitis

Resource links provided by NLM:

MedlinePlus related topics: Diabetes
U.S. FDA Resources

Further study details as provided by University Hospital, Strasbourg, France:

Estimated Enrollment: 90
Study Start Date: March 2008
  Eligibility

Ages Eligible for Study:   20 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion criteria:

  • Patients from 20 to 80 years old
  • A minimum of 10 teeth
  • Healthy volunteers or diabetic patients with or without periodontitis

Exclusion criteria:

  • a course of antibiotics
  • a fungicidal therapy
  • a corticotherapy
  • a hormone therapy
  • a pregnancy
  • persons under guardianship
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00399620

Contacts
Contact: Martine Soell, MD 33 6 74 86 67 36 martine.soell@chru-strasbourg.fr

Locations
France
Département de Parodontologie - Hôpital Civil Recruiting
Strasbourg, France, 67091
Contact: Martine Soell, MD     33.6.74.86.67.36     martine.soell@chru-strasbourg.fr    
Principal Investigator: Martine Soell, MD            
Sub-Investigator: Frédéric Blickle, MD            
Sponsors and Collaborators
University Hospital, Strasbourg, France
Investigators
Study Director: Martine Soell, MD Hôpitaux Universitaires de Strasbourg
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00399620     History of Changes
Other Study ID Numbers: 3739
Study First Received: November 14, 2006
Last Updated: January 9, 2009
Health Authority: France: Ministry of Health

Keywords provided by University Hospital, Strasbourg, France:
Periodontitis
Diabetes
Gingival crevicular fluid
GCF
Saliva
 Chromogranin
Electrophorèse
Western Blot
RT-HPLC

Additional relevant MeSH terms:
Periodontitis
Periodontal Diseases
Mouth Diseases
Stomatognathic Diseases

ClinicalTrials.gov processed this record on May 23, 2013